Recently, Wang et al. presented a preliminary report of the efficacy of the combination of 40 mg weekly selinexor with RGDP or RICE for patients with 11R/R DLBCL with TP53 alterations [12,13]. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.